BioBehavioral Diagnostics, founded in 2004, specializes in the objective measurement of ADHD through the Quotient ADHD Test. This test quantitatively assesses hyperactivity, impulsivity, and inattention, providing valuable insights for the assessment of ADHD. By reporting micro-motion and analyzing shifts in attention state, the test not only aids in diagnosis but also helps engage patients and guardians in the treatment planning process.
The company operates within the Biotechnology, Health Care, and Manufacturing industries. It received a significant $500.00K venture round investment on 28 February 2013, reflecting investor confidence in its innovative approach to ADHD assessment. The identity of the specific investors involved in this round is currently undisclosed.
